Method and system for reversal of interactions between hydrophobically modified biopolymers and vesicles or cell membranes
    1.
    发明授权
    Method and system for reversal of interactions between hydrophobically modified biopolymers and vesicles or cell membranes 有权
    用于逆转疏水改性的生物聚合物和囊泡或细胞膜之间相互作用的方法和系统

    公开(公告)号:US08664199B2

    公开(公告)日:2014-03-04

    申请号:US13209399

    申请日:2011-08-13

    Abstract: A method for reversing gelation of hydrophobically modified biopolymer attached to vesicle or cell membranes. The gelation of hydrophobically modified biopolymer attached to vesicles or cell membranes is reversed by application of a supramolecule, such as cyclodextrin, to the gelled composition. The supramolecule disrupts the interactions between the hydrophobically modified biopolymer and the vesicle or cell membrane, without affecting the structure of the membrane or the hydrophobically modified polymer to which the hydrophobic substituents are attached. A kit for treating wounds that includes a hydrophobically modified biopolymer and a supramolecule. The hydrophobically modified biopolymer is used to stop bleeding and the supramolecule is used to remove the hydrophobically modified biopolymer.

    Abstract translation: 疏水改性的生物聚合物与囊泡或细胞膜连接的凝胶化方法。 连接到囊泡或细胞膜上的疏水改性的生物聚合物的凝胶化通过将超分子如环糊精施加到胶凝组合物来逆转。 超分子破坏疏水改性生物聚合物与囊泡或细胞膜之间的相互作用,而不影响疏水性取代基所连接的膜或疏水改性聚合物的结构。 用于治疗包含疏水改性生物聚合物和超分子的伤口的试剂盒。 疏水改性的生物聚合物用于止血,超分子用于除去疏水改性的生物聚合物。

    METHOD AND SYSTEM FOR REVERSAL OF INTERACTIONS BETWEEN HYDROPHOBICALLY MODIFIED BIOPOLYMERS AND VESICLES OR CELL MEMBRANES
    2.
    发明申请
    METHOD AND SYSTEM FOR REVERSAL OF INTERACTIONS BETWEEN HYDROPHOBICALLY MODIFIED BIOPOLYMERS AND VESICLES OR CELL MEMBRANES 有权
    水解改性生物聚合物与VESICLES或细胞膜之间相互作用的方法和系统

    公开(公告)号:US20120058970A1

    公开(公告)日:2012-03-08

    申请号:US13209399

    申请日:2011-08-13

    Abstract: A method for reversing gelation of hydrophobically modified biopolymer attached to vesicle or cell membranes. The gelation of hydrophobically modified biopolymer attached to vesicles or cell membranes is reversed by application of a supramolecule, such as cyclodextrin, to the gelled composition. The supramolecule disrupts the interactions between the hydrophobically modified biopolymer and the vesicle or cell membrane, without affecting the structure of the membrane or the hydrophobically modified polymer to which the hydrophobic substituents are attached. A kit for treating wounds that includes a hydrophobically modified biopolymer and a supramolecule. The hydrophobically modified biopolymer is used to stop bleeding and the supramolecule is used to remove the hydrophobically modified biopolymer.

    Abstract translation: 疏水改性的生物聚合物与囊泡或细胞膜连接的凝胶化方法。 连接到囊泡或细胞膜上的疏水改性的生物聚合物的凝胶化通过将超分子如环糊精施加到胶凝组合物来逆转。 超分子破坏疏水改性生物聚合物与囊泡或细胞膜之间的相互作用,而不影响疏水性取代基所连接的膜或疏水改性聚合物的结构。 用于治疗包含疏水改性生物聚合物和超分子的伤口的试剂盒。 疏水改性的生物聚合物用于止血,超分子用于除去疏水改性的生物聚合物。

    Pharmaceutical combination of pazopanib and topotecan to treat neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human
    8.
    发明授权
    Pharmaceutical combination of pazopanib and topotecan to treat neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human 失效
    帕可帕尼与托泊替康的药物联合治疗人类的神经母细胞瘤,骨肉瘤和横纹肌肉瘤

    公开(公告)号:US08709420B2

    公开(公告)日:2014-04-29

    申请号:US13990515

    申请日:2011-11-23

    CPC classification number: A61K31/506 A61K31/4375 A61K31/4745 A61K2300/00

    Abstract: The present invention relates to methods of treating neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a neuroblastoma treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and (S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione, or a pharmaceutically acceptable salt thereof, to a human in need thereof.

    Abstract translation: 本发明涉及治疗人类的神经母细胞瘤,骨肉瘤和横纹肌肉瘤的方法以及用于这种治疗的药物组合。 特别地,该方法涉及神经母细胞瘤治疗方法,其包括施用5 - [[4 - [(2,3-二甲基-2H-吲唑-6-基)甲基氨基] -2-嘧啶基]氨基] -2-甲基苯磺酰胺, 或其药学上可接受的盐,和(S)-10 - [(二甲基氨基)甲基] -4-乙基-4,9-二羟基-1H-吡喃并[3',4':6,7]吲哚并[1,2 b]喹啉-3,14-(4H,12H) - 二酮或其药学上可接受的盐。

Patent Agency Ranking